Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .
Latest Developments forMitsubishi Chemical Holdings Corp
Latest Key Developments inDiversified
- Ashland Global Sees Q3 Earnings From Continuing Operations In Range Of $0.36 To $0.38 Per Share
- Brenntag AG Adjusts Its Outlook For Full Year 2019
- Rec Silicon Executes Workforce Reduction In Moses Lake, Washington
- BASF India To Divest Stilbene Based Optical Brightening Agents Business To Archroma India